85

DAFTAR PUSTAKA

Abba, M., Patil, N., & Allgayer, H., 2014. MicroRNAs in the Regulation of MMPs

and Metastasis. Cancers, 6(2), 625–45.

Ali, AY., Farrand, L., Kim, JY., Byun, S., Suh, JY., Lee, HJ., Tsangi, BK. 2012.

Molecular determinants of ovarian cancer chemoresistance: new insights into

an old conundrum. Ann. N.Y. Acad. Sci., 1271, Pages : 58–67

Aziz, FM. 2009. Gynecological Cancer in Indonesia. J Gynecol Oncol, 20(1):pp.8-10

Baranwal, S., & Alahari, S. K., 2010. miRNA control of tumor cell invasion and

metastasis. Int J Cancer126(6): 1283–1290.

Brabletz T .2012.To differentiate or not—routes towards metastasis. Nature Reviews

Cancer 12: 425–436.

Berek, JS; Fu, YS; Hacker, NF. 2002. Ovarian Cancer in Novak’s Gynecology 13th

Edition. Williams & Wilkins, Pensylvania : pp.1245-1320.

Blondal, T., Jensby Nielsen, S., Baker, A., Andreasen, D., Mouritzen, P., Wrang

Teilum, M., & Dahlsveen, IK., 2013, Assessing sample and miRNA profile

quality in serum and plasma or other biofluids. Methods, 59(1), S1–6

Bouyssou, JMC., Manier, S., Huynh, D., Issa, S., Roccaro, AM., & Ghobrial, IM.,

2014. Regulation of microRNAs in cancer metastasis.Biochim Biophys Acta,

1845(2), 255–65.

Britton, C., Winter, A. D., Gillan, V., & Devaney, E., 2014, MicroRNAs of Parasitic

Helminths – Identification, Characterization and Potential as Drug Targets. Int

J Parasitol Drugs Drug Resist, 4(2), 85–94.

Buys, SS., Partridge, E., Black, A., et al., 2011. Effect of screening on ovarian cancer

mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening

randomized controlled trial. J Am Med Assoc, 22 : pp.2295– 2302.

Calin, G. a, & Croce, C. M., 2006. MicroRNA signatures in human cancers. Nature

Rev Cancer6(11): 857–66.

Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, et al. (2010). Loss of

miR-200c expression induces an aggressive, invasive, and chemoresistant

phenotype in non–small cell lung cancer. Int J Cancer 8: 1207– 1216.

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

86

Chandi, C. Mandal, A. Nag, S. Kumar. 2015. A Comprehensive Review on miR-

200c, A Promising Cancer Biomarker with Therapeutic Potential.16(12): 1381

– 1403.

Chen, B., Li, H., Zeng, X., Yang, P., Liu, X., Zhao, X., & Liang, S., 2012, Roles of

microRNA on cancer cell metabolism. J Transl Med, 10, 228.

Chen, H.-C., Chen, G.-H., Chen, Y.-H., Liao, W.-L., Liu, C.-Y., Chang, K.-P., et al.,

2009. MicroRNA deregulation and pathway alterations in nasopharyngeal

carcinoma. Br J Cancer, 100(6): 1002–11.

Chen, Xi., Zhang, Junfeng, Zen, Ke., Zhang, Chen-Yu, 2008, 2011. MicroRNAs as

Blood-based Biomarkers of Cancer. Dalam Cho, C. S. William (Eds).

MicroRNAs in Cancer Translational Research. Springer : Pp.499-532

Chen, Y., Lan, Q., Zheng, T., Zhao, N., Holford, T. R., Lerro, C., et al., 2013.

Polymorphisms in JAK/STAT Signaling Pathway Genes and Risk of Non-

Hodgkin Lymphoma. Leuk Res37(9): 1120–1124.

Chinen, T., Komai, K., Muto, G., Morita, R., Inoue, N., Yoshida, H., et al.,2011.

Prostaglandin E2 and SOCS1 have a role in intestinal immune tolerance. Nat

Commun,2(2): 190.

Cullen, B. R., 2013. MicroRNAs as Mediators of Viral Immune Evasion Bryan. Nat

Immunol., 14(3): 205–210.

De Martel C., Ferlay J., Franceschi S., 2012. Global Burden of Cancer Attributable to

Infections in 2008: A Review and Synthetic Analysis. Lancet Oncol, 13 :607-

615.

Gao, Y.C. and Wu J. 2015. MicroRNA-200c and microRNA-141 as potential

diagnostic and prognostic biomarkers for ovarian cancer. Tumour biology :

International Society for Oncodevelopmental Biology and Medicine. 36:4843–

4850.

Garzon, R., Marcucci, G., Croce, CM. 2010. Targeting microRNAs in cancer :

rationale, strategies and challenges. Nat Rev Drug Discov, 9(10) : pp.775-789

George, G.P. dan Mittal, R.D. 2010. microRNAs : Potential Biomarker in Cancer.

Indian J Clin Biochem, (1) : pp. 4-14

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

87

Goda G Muralidhar dan Maria V Barbolina. 2015. The miR-200 Family: Versatile

Players in Epithelial Ovarian Cancer. Int. J. Mol. Sci.16 : pp.16833-16847

Hammell, M., Long, D., Zhang, L., Lee, A., Carmack, S., Han, M., et.al. 2008.

mirWIP: microRNA Target Prediction Based on miRNP Enriched Transcripts.

Nat Methods, 5(9) : pp.813–819

Harrison, D.A., 2012. The Jak/STAT pathway. Cold Spring Harb Perspect Biol,4(3):

2012–2015.

Huang, Y., Yang, Y. B., Zhang, X. H., Yu, X. L., Wang, Z. B., et al., 2013.

MicroRNA-21 gene and cancer. Med Oncol30(376).

IAIRC, 2014, World Cancer Report 2014.

Iorio, M. V, & Croce, C. M., 2012. MicroRNA dysregulation in cancer : diagnostics ,

monitoring and therapeutics . A comprehensive review. EMBO Mol Med,

143–159.

Jaime Prat. FIGO’s staging classification for cancer of the ovary, fallopian tube, and

peritoneum: a bridged republication. 2015. Gynecol Oncol, 26 (2) : pp.87-89

Jelovac, D; Armstrong, DK. 2011. Recent Progress in the Diagnosis and treatment of

Ovarian Cancer.Ca Cancer J Clin, 61 : pp.183–203

Kaku, Tsunehisa; Ogawa, Shinji; Kawano, Yfoshiaki; Ohishi, Yoshihiro; Kobayashi,

Hiroaki; Hirakawa, Toshio; Nakano, Hitoo 2003. Histological classification of

ovarian cancer. Med Electron Microsc, 36 : pp.9–17

Kosaka, N., Iguchi, H., & Ochiya, T., 2010. Circulating microRNA in body fluid: a

new potential biomarker for cancer diagnosis and prognosis. Cancer

Sci,101(10): 2087–92.

Krol, J., Loedige, I., & Filipowicz, W., 2010. The widespread regulation of

microRNA biogenesis, function and decay. Nat Rev Genet, 11(9): 597–610.

Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y,

Kinoshita K, Saito S, Baba Y, Baba H. MicroRNA-200b regulates cell

proliferation, invasion, and migration by directly targeting ZEB2 in gastric

carcinoma. Annals of surgical oncology. 2012; 19.3:S656–664.

Lee, A. W. M., Au, J. S. K., Teo, P. M. L., Leung, T. W., Chua, D. T. T., Sze, W. M.,

et al., 2004, Staging of Nasopharyngeal Carcinoma : Suggestions for

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

88

Improving the Current UICC / AJCC Staging System, Clin Oncol (R Coll

Radiol) 1, 269–276.

Lee, Y. S., & Dutta, A., 2010. MicroRNAs in cancer. Annu Rev Pathol (4): 199–227.

Leitner, A., 2009, MicroRNA Target Prediction : Institute of Genomic and

Bioinformatics. Graz University of Technology (Unpublished).

Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A, &

Vasconcelos, M. H., 2011. MicroRNA regulation of core apoptosis pathways

in cancer. Eur J Cancer,47(2): 163–74.

Lin, Z., & Flemington, E. K., 2011. miRNAs in the pathogenesis of oncogenic human

viruses Zhen. Cancer Lett,305(2): 186–199.

Liu, Michelle X; Chan, David W; Ngan, Hextan YS. 2012. Mechanisms of

Chemoresistance in Human Ovarian Cancer at a Glance. Gynecol Obstet, 2 : 3

Liu, L., Li, W., Wei, X., Cui, Q., Lou, W., Wang, G., et al., 2013. Potent antitumor

activity of oncolytic adenovirus-mediated SOCS1 for hepatocellular

carcinoma. Gene Ther,20(1): 84–92.

Liu L, Qiu M, Tan G, Liang Z, Qin Y, Chen L, Chen H, Liu J. 2014.miR-200c

Inhibits invasion, migration and proliferation of bladder cancer cells through

down-regulation of BMI-1 and E2F3. Journal of translational medicine.

12:305.

Livak, KJ., Schmittgen, TD. 2001. Analysis of Relative Gene Expression Data Using

Real-Time Quantitative PCR and the 2-∆∆Cq Method. METHODS, 25 : pp. 402–

408

Lodes, MJ; Caraballo, M; Suciu, D; Munro, S; Kumar, A; Anderson, B. 2009.

Detection of cancer with serum miRNAs on an oligonucleotide microarray.

PLoS ONE, 4 : pp.6229

Lu, J., Xu, X., Liu, X., Peng, Y., Zhang, B., Wang, L., et al., 2014. Predictive value

of miR-9 as a potential biomarker for nasopharyngeal carcinoma metastasis.

Br J Cancer110(2): 392–8.

Mao, F., Leung, WY., Xin, X. 2007. Characterization of EvaGreen and the

implication of its physicochemical properties for qPCR applications. BMC

Biotechnology, 7 : 76

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

89

Menor, M., Ching, T., Zhu, X., Garmire, D., Garmire, LX. 2014. mirMark: a site-

level and UTR-level classifier for miRNA target prediction. Genome Biology,

15 : pp.500

Nakada, C. Matsuura, K. Tsukamoto, Y. Tanigawa, M. Yoshimoto, T. Narimatsu, T.

Nguyen, et al. 2008. Genome-wide microRNA expression profiling in renal

cell carcinoma: significant down-regulation of miR-141 and miR-200c. The

Journal of pathology. 216:418–427.

Ng Ek., Chong W. W.,Jin H. 2009. Differential Expression of microRNAs in Plasma

of Patients with Colorectal Cancer: a Potential marker for Colorectal

Screening. Gut, 58:1375-81.

Nicolleta Colombo. 2014. Optimising the treatment of the partially platinum-sensitive

relapsed ovarian cancer patient. European Journal of Cancer Supplements.

12(2) : pp.7–12

Noonan, E. J., Place, R. F., Li, L. C., 2008, 2011. MicroRNAs in Predicting

Radiotherapy and Chemoterapy Respone. Dalam Cho, C. S. William (Eds).

MicroRNAs in Cancer Translational Research. Springer : Pp.415-448.

Pacurari M, Addison JB, Bondalapati N, Wan Y-W, Luo D. (2013). The microRNA-

200 family targets multiple non-small cell lung cancer prognostic markers in

H1299 cells and BEAS-2B cells. International journal of oncology 43: 548–

560.

Pedro M Costa dan Maria C Pedroso de Lima. 2013. MicroRNAs as Molecular

Targets for Cancer Therapy: On the Modulation of MicroRNA Expression.

Pharmaceuticals, 6(10) : 1195–1220

Pi-Lin, S; Yen-Hou, C; Kuan-Chong, C; Chi-Mu, C. 2014. Global distribution pattern

of histological subtypes of epithelial ovarian cancer: A database analysis and

systematic review. Gynecologic Oncology, 133 : 147–154

Pritchard, CC., Cheng, HH., Tewari, M. 2012. microRNA profiling : approaches and

considerations. Nat Rev. 13 : 358-69

Rosen, DG; Yang, GL; Guangzhi; Mercado-Uribe, I; Chang, B; Xoai, XZ; et.al.

2010. Ovarian cancer: pathology, biology, and disease models. Front Biosci,

14 : 2089-2102

Ruly Widagdo. 2009. Angka Harapan Hidup Penderita Kanker Ovarium di Rumah

Sakit Sardjito. Tesis Fakultas Kedokteran Universitas Gadjah Mada

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

90

Rusnita, T; Prijono, I. Ekspresi P53, Bcl-2 dan Nm23-H1 pada Karsinoma Ovarium

Tipe Serosum dan Musinosum serta Hubungannya dengan Stadium dan

Derajat Histologi. Majalah Patologi; 23(2) : 13-19

Sasi, W., Sharma, A. K., & Mokbel, K., 2014. The role of suppressors of cytokine

signalling in human neoplasms. Mol Biol Int.

Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K., 2014. Clinical relevance

of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol, 11(3):145-

56.

Song, C. Liu, L.Z. Pei, X.Q. Liu, X. Yang, L. Ye, F. Xie, X. Chen, J. Tang, H. Xie, X.

2015. miR-200c inhibits breast cancer proliferation by targeting KRAS.

Oncotarget. 6(33):34968-78.

Soslow, A Robert. 2008. Histologic Subtypes of Ovarian Carcinoma: An Overview.

International Journal of Gynecological Pathology, 27 : 161–174

Tang, H,.Deng, M. Tang, Y. Xie, X. Guo, J. Kong, Y. Ye, F. Su, Q. Xie, X. 2013.

miR-200b and miR-200c as prognostic factors and mediators of gastric cancer

cell progression. Clinical cancer research. American Association for Cancer

Research. 19:5602–5612.

Tejero, R., Navarro, A., Campayo, M., Vinolas, N., Marrades, RM.,Cordeiro. A.,

et.al. 2014. miR-141 and miR-200c as Markers of Overall Survival in Early

Stage Non-Small Cell Lung Cancer Adenocarcinoma. PLoS ONE 9(7):

e101899.

Teng, Y. X. Su, X. Zhang, Y. Zhang, C. Li, W. Niu, C. Liu, K.Qu. 2016. miRNA-

200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence

based on miRNA meta-signature and clinical investigations. Oncotarget.

Vester, B dan Wengel, J. 2004. LNA (Locked Nucleic Acid) : High Affinity

Targeting of Complementary RNA and DNA. Biochemistry, 23(42) : 13233-

40

Wang, L., Wang, C., Jin, S., Donghui, Q., Huanchun, Y. 2015. Expression of NF-κB

and PTEN in primary epithelial ovarian carcinoma and the correlation with

chemoresistance. Int J Clin Exp Pathol, 8(9) : 10953-10963

Wang, WT; Zhao, YN; Yan, JX; Weng, MY; Wang, Y; Chen, YQ; et.al. 2014.

Differentially expressed microRNAs in the serum of cervical squamous cell

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/

91

carcinoma patients before and after surgery. Journal of Hematology and

Oncology, 7 : 6

Wang, J; Zhang, KY; Liu, SM; Sen, S. 2014. Tumor-Associated Circulating

MicroRNAs as Biomarkers of Cancer. Molecules, 19 : 1912-1938

Wen-Tao, W. dan Chen, Y-Q., 2014, Circulating miRNAs in Cancer : from Detection

to Therapy. Journal of Hematology and Oncology, 7 : 86

William, C.S, Cho. 2011. MicroRNAs in Cancer Translational Research. New York :

Springer.

Yu DS, Lv G, Mei XF, Cao Y, Wang YF, Wang YS, Bi YL. 2014. MiR-200c

regulates ROS-induced apoptosis in murine BV-2 cells by targeting FAP-1.

Spinal cord. 2014.185.

Zeng, X., Xiang, J., Wu, M., Xiong, W., Tang, H., Deng, M., et al., 2012. Circulating

miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive

biomarkers in nasopharyngeal carcinoma. PloS One,7(10).

Zhang, Y., Liu, D., Chen, X., Li, J., Li, L., Bian, Z., et al., 2010. Article Secreted

Monocytic miR-150 Enhances Targeted Endothelial Cell Migration. Mol

Cell,39: 133–144.

Zubakov, D.,Boersma, A.W.M., Choi,Y., van Kuijk, P.F., Wiemer, E.A.C., Kayser,

M. 2010. MicroRNA markers for forensic body fluid identification obtained

from microarray screening and quantitative RT-PCR confirmation. Int J Legal

Med,(124):217-226.

PERBEDAAN EKSPRESSI MIR-200c PADA PLASMA ORANG SEHAT, PASIEN TUMOR OVARIUM DANPASIEN KANKER OVARIUM FERDINANDUS K PUKAN, Prof. dr. Sofia Mubarika H., M.Med.Sc., Ph.D.; Dr. Med. dr. Indwiani Astuti Universitas Gadjah Mada, 2017 | Diunduh dari http://etd.repository.ugm.ac.id/